TARA Quote, Financials, Valuation and Earnings

Aura Biosciences has a net margin of -- compared to Protara Therapeutics's net margin of --. Protara Therapeutics's return on equity of -- beat Aura Biosciences's return on equity of --.

Protara Therapeutics has a consensus price target of $22.17, signalling upside risk potential of 691.67%. On the other hand Aura Biosciences has an analysts' consensus of $21.50 which suggests that it could grow by 243.45%. Given that Protara Therapeutics has higher upside potential than Aura Biosciences, analysts believe Protara Therapeutics is more attractive than Aura Biosciences.

Protara Therapeutics has a beta of 1.350, which suggesting that the stock is 34.998% more volatile than S&P 500. In comparison Aura Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aura Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics pays -- of its earnings as a dividend. Aura Biosciences pays out -- of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than Aura Biosciences quarterly revenues of --. Protara Therapeutics's net income of -$11.9M is higher than Aura Biosciences's net income of -$27.5M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while Aura Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus -- for Aura Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Protara Therapeutics's net margin of -49.65%. Protara Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Protara Therapeutics has a consensus price target of $22.17, signalling upside risk potential of 691.67%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.57%. Given that Protara Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Protara Therapeutics is more attractive than NovaBay Pharmaceuticals.

Protara Therapeutics has a beta of 1.350, which suggesting that the stock is 34.998% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Protara Therapeutics's net income of -$11.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Protara Therapeutics's net margin of --. Protara Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Protara Therapeutics has a consensus price target of $22.17, signalling upside risk potential of 691.67%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1498.17%. Given that Theriva Biologics has higher upside potential than Protara Therapeutics, analysts believe Theriva Biologics is more attractive than Protara Therapeutics.

Protara Therapeutics has a beta of 1.350, which suggesting that the stock is 34.998% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Protara Therapeutics's net income of -$11.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.